These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559 [TBL] [Abstract][Full Text] [Related]
3. A clinical study of transdermal contraceptive patch in Thai adolescence women. Piyasirisilp R; Taneepanichskul S J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975 [TBL] [Abstract][Full Text] [Related]
4. [Safety evaluation of a transdermal contraceptive system with an oral contraceptive]. Radowicki S; Skórzewska K; Szlendak K Ginekol Pol; 2005 Nov; 76(11):884-9. PubMed ID: 16566363 [TBL] [Abstract][Full Text] [Related]
5. [A transdermal form of combined hormonal contraceptives (EVRA)]. Fanta M Ceska Gynekol; 2003 Oct; 68(5):341-5. PubMed ID: 14692356 [TBL] [Abstract][Full Text] [Related]
7. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception. Goa KL; Warner GT; Easthope SE Treat Endocrinol; 2003; 2(3):191-206. PubMed ID: 15966567 [TBL] [Abstract][Full Text] [Related]
8. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. White T; Jain JK; Stanczyk FZ Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897 [TBL] [Abstract][Full Text] [Related]
9. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra). Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313 [TBL] [Abstract][Full Text] [Related]
10. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Jick S; Kaye JA; Li L; Jick H Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129 [TBL] [Abstract][Full Text] [Related]
16. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. Creasy GW; Fisher AC; Hall N; Shangold GA J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776 [TBL] [Abstract][Full Text] [Related]
17. High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study. Jakimiuk AJ; Crosignani PG; Chernev T; Prilepskaya V; Bergmans P; Von Poncet M; Marelli S; Lee EJ Gynecol Endocrinol; 2011 Oct; 27(10):849-56. PubMed ID: 21142776 [TBL] [Abstract][Full Text] [Related]
18. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra). Zieman M Fertil Steril; 2002 Feb; 77(2 Suppl 2):S1-2. PubMed ID: 11849629 [No Abstract] [Full Text] [Related]
19. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834 [TBL] [Abstract][Full Text] [Related]
20. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Jick SS; Kaye JA; Russmann S; Jick H Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]